StageMark is a development stage company that is working to provide an early identification and monitoring solution for inflammatory diseases such as lupus.

 

StageMark's platform, CB-CAPs (Cell-Bound Complement Activation Products) was discovered by Dr. Sue Manzi, MD, MPH and Joseph Ahearn, MD, Ph.D., rheumatology clinicians and scientists from the University of Pittsburgh Medical Center (UPMC) Lupus Center of Excellence at Magee Women’s Hospital.

 

Through their clinical practice, more than 300 lupus patients have been tested, generating promising support for the CB-CAPs applicability for lupus identification and assessment of disease activity.

 

Contact:  412.481.4400